Philipp Ianevski

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

O. Kallioniemi, D. Ungureanu, A. Murumägi, 2021, Translational oncology.

Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma

Suleiman A. Khan, T. Aittokallio, V. Pietiäinen, 2022, British Journal of Cancer.

Breeze: an integrated quality control and data analysis application for high-throughput drug screening

Krister Wennerberg, Tero Aittokallio, Bhagwan Yadav, 2020, Bioinform..

High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma

O. Monni, T. Salo, Aini Hyytiäinen, 2021, Scientific Reports.